Business
Boston Scientific develops minimally invasive medical devices across cardiovascular, endoscopy, urology and other specialties.
Boston Scientific: Revenue grew 19.9% to $20.074B from $16.747B. Net income grew 56.7% to $2.892B from $1.846B. Free cash flow grew 38.3% to $3.658B from $2.645B. Operating margin expanded 246 bps to 18.00%. Boston Scientific's principal statistical and annual-change screens add no overriding warning to the reported profit and cash-flow record.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 19.9%OK
- Profitability — Net income grew 56.7% to $2.892B from $1.846BOK
- Cash flow — Free cash flow grew 38.3% to $3.658B from $2.645BOK
- Margins — Operating margin expanded 246 bps to 18.00%OK
- Accounting — No overriding statistical warningNote
- Insiders — 4 purchases and 11 salesOK
Where the revenue comes from
Fiscal 2025, as BOSTON SCIENTIFIC CORP reports it. History and quarterly detail are in the app.
- Cardiovascular$13.3B
- MedSurg$6.8B
Leadership changes
From BOSTON SCIENTIFIC CORP's own filings, the day they're filed.
- Catherine R. Smith · director · appointmenteff. 2026-02-18
- Yoshiaki Fujimori · member · departureeff. 2026-02-02
- John E. Sununu · member · departureeff. 2025-10-22
Latest filings
- 8-K · Company announcement2026-08-26
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-05-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BOSTON SCIENTIFIC CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.